We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Revolutionary AI Tool Transforms Disease Visualization

By LabMedica International staff writers
Posted on 10 Feb 2025

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. More...

Occasionally, alterations in these instructions—known as mutations—can interfere with this process and cause disease. Omics refers to the study of genes, proteins, and other molecular data to explore the body's functions and how diseases evolve. Now, an artificial intelligence (AI) tool is assisting in converting vast, complex biological data into two-dimensional circular visuals. By mapping this data, the tool might offer clinicians and researchers a novel method for visualizing disease patterns, such as those found in cancer and neurological disorders, which could aid in directing personalized treatments. Additionally, it may provide an intuitive means of exploring disease mechanisms and interactions.

Developed by researchers at Mayo Clinic (Rochester, MN, USA), the tool called OmicsFootPrint helps to clarify these complexities by transforming data—such as gene activity, mutations, and protein levels—into vibrant, circular maps that offer a clearer understanding of what’s occurring within the body. In their study, the researchers employed OmicsFootPrint to examine drug responses and cancer multi-omics data. The tool successfully distinguished between two types of breast cancer—lobular and ductal carcinomas—with an average accuracy of 87%. In lung cancer, it showed over 95% accuracy in identifying two types: adenocarcinoma and squamous cell carcinoma. The findings, published in Nucleic Acids Research, revealed that combining various types of molecular data yields more accurate results than using just a single type.

The OmicsFootPrint also demonstrates promise in generating meaningful insights even with limited datasets. It utilizes advanced AI techniques that learn from existing data and apply this knowledge to new situations, a process known as transfer learning. For instance, it assisted researchers in achieving over 95% accuracy in identifying lung cancer subtypes with less than 20% of the usual data volume. To further enhance its accuracy and insights, the OmicsFootPrint framework incorporates a sophisticated method called SHAP (SHapley Additive exPlanations). SHAP highlights the key markers, genes, or proteins that impact the results, aiding researchers in understanding the underlying factors driving disease patterns. In addition to research, OmicsFootPrint is also intended for clinical use. It compresses large biological datasets into compact images that occupy only 2% of the original storage space. This compression could simplify the integration of the images into electronic medical records, potentially guiding future patient care. The research team is working on expanding OmicsFootPrint to explore additional diseases, including neurological conditions and other complex disorders. They are also focusing on updates to enhance the tool's accuracy and flexibility, such as the ability to identify new disease markers and drug targets.

"Data becomes most powerful when you can see the story it's telling," says Krishna Rani Kalari, Ph.D., lead author of the study and associate professor of biomedical informatics at Mayo Clinic's Center for Individualized Medicine. "The OmicsFootPrint could open doors to discoveries we haven't been able to achieve before."


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Gel Cards
DG Gel Cards
New
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.